Nitrase Therapeutics

About:

Nitrase Therapeutics is developing drugs against newly discovered nitration enzyme(s).

Website: https://nitrasetx.com/

Top Investors: Alexandria Venture Investments, AbbVie, Bristol-Myers Squibb, Dementia Discovery Fund, Michael J. Fox Foundation

Description:

Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is on Parkinson's disease, the company aims to expand its proprietary platform to include other disease indications.

Total Funding Amount:

$45.1M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Jackson, Mississippi, United States

Founded Date:

2017-01-01

Founders:

Irene Griswold-Prenner

Number of Employees:

11-50

Last Funding Date:

2021-11-02

IPO Status:

Private

Industries:

© 2025 bioDAO.ai